Exosens (EXENS) Stock Overview
Engages in the development, manufacture, and sale of electro-optical technologies in the fields of amplification, and detection and imaging in France, rest of Europe, North America, Asia, Oceania, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EXENS from our risk checks.
EXENS Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Exosens Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €42.45 |
| 52 Week High | €46.60 |
| 52 Week Low | €16.84 |
| Beta | 0 |
| 1 Month Change | 25.59% |
| 3 Month Change | 31.83% |
| 1 Year Change | 93.22% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 88.67% |
Recent News & Updates
Elevated Defense Spending Will Challenge Overvaluation And Unleash Upside
Growth and profitability expectations rely on sustained global defense spending, rapid demand capture, and seamless operational execution, making them vulnerable to defense cycle shifts and integratiMarket Participants Recognise Exosens' (EPA:EXENS) Revenues Pushing Shares 27% Higher
May 29
Recent updates
Elevated Defense Spending Will Challenge Overvaluation And Unleash Upside
Growth and profitability expectations rely on sustained global defense spending, rapid demand capture, and seamless operational execution, making them vulnerable to defense cycle shifts and integratiMarket Participants Recognise Exosens' (EPA:EXENS) Revenues Pushing Shares 27% Higher
May 29€31.58 - That's What Analysts Think Exosens (EPA:EXENS) Is Worth After These Results
Mar 06Optimistic Investors Push Exosens (EPA:EXENS) Shares Up 37% But Growth Is Lacking
Mar 05Exosens' (EPA:EXENS) Intrinsic Value Is Potentially 96% Above Its Share Price
Feb 14Shareholder Returns
| EXENS | FR Aerospace & Defense | FR Market | |
|---|---|---|---|
| 7D | -6.2% | -3.7% | -0.5% |
| 1Y | 93.2% | 23.6% | -3.0% |
Return vs Industry: EXENS exceeded the French Aerospace & Defense industry which returned 23.6% over the past year.
Return vs Market: EXENS exceeded the French Market which returned -3% over the past year.
Price Volatility
| EXENS volatility | |
|---|---|
| EXENS Average Weekly Movement | 6.5% |
| Aerospace & Defense Industry Average Movement | 6.4% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in FR Market | 10.6% |
| 10% least volatile stocks in FR Market | 2.8% |
Stable Share Price: EXENS has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: EXENS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1937 | 1,308 | Jerome Cerisier | www.exosens.com |
Exosens engages in the development, manufacture, and sale of electro-optical technologies in the fields of amplification, and detection and imaging in France, rest of Europe, North America, Asia, Oceania, Africa, and internationally. It offers image intensifier tubes; ultra violet, short and long wave infrared, visible - near infrared, and mid wave infrared cameras, as well as enhanced vision equipment; ion and electron, scintillation, and single photon detection products; x-ray components, neutronic imaging products, and image intensifiers for scientific applications; and gamma and neutron detectors, and mineral insulated extensions. The company also provides power tubes and microwave devices; and methane airborne detection solutions.
Exosens Fundamentals Summary
| EXENS fundamental statistics | |
|---|---|
| Market cap | €2.15b |
| Earnings (TTM) | €25.53m |
| Revenue (TTM) | €394.08m |
Is EXENS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXENS income statement (TTM) | |
|---|---|
| Revenue | €394.08m |
| Cost of Revenue | €164.74m |
| Gross Profit | €229.34m |
| Other Expenses | €203.81m |
| Earnings | €25.53m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jul 31, 2025
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 58.20% |
| Net Profit Margin | 6.48% |
| Debt/Equity Ratio | 60.7% |
How did EXENS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/12 17:37 |
| End of Day Share Price | 2025/06/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exosens is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laurent Gelebart | BNP Paribas Exane |
| Charles Armitage | Citigroup Inc |
| David Perry | J.P. Morgan |